The Pulmonary Hypertension Association (PHA) office phone system is experiencing intermittent outages as of Friday, Feb. 16, 2018 at 9:45 a.m. EST. We are working on a solution as quickly as possible. If you need to contact PHA with general inquiries about membership, Conference, store orders or other questions, and are unable to reach us
PHA Accreditation Program Assures Access to Specialized Care for Thousands With Often-Misdiagnosed Deadly Lung Disease
Silver Spring, MD (February 15, 2018) – A national accreditation program launched by the Pulmonary Hypertension Association (PHA) assures that more than 12,000 people with a life-threatening lung disease are getting care from clinicians who specialize in their often-misdiagnosed condition. Pulmonary hypertension (PH), also known as high blood pressure of the lungs, affects adults
Seeking Financial Assistance Because of Caring Voice Developments? Previous CVC Clients Should Make That Clear When Contacting Manufacturers.
In January, the Department of Health and Humans Services informed companies that manufacture PH medications that they would be permitted to provide one year of free medication to some individuals who received assistance from the Caring Voice Coalition as of Nov. 28, 2017. To be eligible, a PH patient must have health insurance through a
Study looks at a theory that adding immunoadsorption, or the process of filtering out antibodies from the blood, in addition to other PH therapies may help improve outcomes for people with idiopathic pulmonary arterial hypertension. by Phyllis Hanlon, Contributing Writer People with idiopathic pulmonary arterial hypertension (IPAH), a type of WHO Group 1 PH (PAH,
WHO Group 1 PH (PAH, pulmonary arterial hypertension) can appear by itself of be associated with other medical conditions including connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). Although CTD-associated PAH is very common in people who have PAH, PAH is extremely uncommon among the many people with SLE. Because of this, a
PHA was recently made aware of a national shortage of the diluent used for mixing some PH medications. The shortage is a result of product manufactures who have been affected by the 2017 hurricane season. The specialty pharmacies that deliver PH medications are working to monitor available supplies and purchase as much inventory as possible.
Investigator Applications are now being accepted for the Research Room at PHA’s 2018 International PH Conference and Scientific Sessions. The Research Room helps researchers further their studies by providing the opportunity for collection of data, including phenotypic information and biological specimens, from the largest gathering of pulmonary hypertension patients in the world. Impact the field
by Phyllis Hanlon, Contributing Writer WHO Group 1 PH (PAH, pulmonary arterial hypertension) is a progressive and chronic disease. There currently is no cure. In PAH, the arteries in the lungs become narrow, thickened or stiff, which causes high blood pressure in the lungs. The disease can present in several forms, one of which
Friday, February 9th, 2018, 3:00 p.m. ET Josanna M. Rodriguez-Lopez, M.D., Massachusetts General Hospital This webinar will focus on WHO Group 4 pulmonary hypertension (PH), chronic thromboembolic pulmonary hypertension (CTEPH), and will include information about what makes CTEPH unique from other types of PH and why it is important to rule out CTEPH in
On Monday, January 15, 2018, President Trump signed into law the Recognize, Assist, Include, Support and Engage (RAISE) Family Caregivers Act calling for a national strategy to address the needs of family caregivers. This bipartisan legislation directs the Department of Health and Human Services (HHS) to develop and make publicly available a National Family Caregiving Strategy that identifies recommended actions